Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Drug Found to Limit Allergic Reaction to Peanuts

By HospiMedica staff writers
Posted on 27 Mar 2003
A study has shown that an experimental drug can help people with peanut allergies avoid life-threatening reactions. More...
The study was published in the March 14, 2003, issue of The New England Journal of Medicine and was also presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in Denver (CO, USA).

Food allergy symptoms can range from nausea and itching to anaphylactic shock and death. Researchers found that an anti-IgE antibody raised the average level at which study participants began reacting to peanuts, from about half a peanut to almost nine peanuts. They estimate that most of the 50-100 US annual fatal reactions to peanuts occur after an allergic person accidentally eats the equivalent of just one or two peanuts. Existing medications, including epinephrine, are taken only after the peanuts have been eaten and are not always effective.

The IgE molecule binds to a group of cells called mast cells, which then trigger the allergic response. The experimental drug, TNX-901, is a genetically engineered antibody that binds to the IgE molecule and prevents it from triggering allergic response. Stopping the response before it begins is considered a major advance. In the study, nearly a quarter of the patients receiving the highest dose of the drug consumed the equivalent of about 24 peanuts with no reaction. While many of them still reacted to peanuts after the injections, they could eat more peanuts without a reaction and reacted less vigorously to the peanuts they did eat.

TNX-901 was developed by Tanox (Houton, TX, USA). The study was conducted by researchers from the National Jewish Medical and Research Center (Denver, CO, USA) and the Mount Sinai School of Medicine (New York, NY, USA).

"Anti-IgE therapy is not a cure for peanut allergy,” said Hugh Sampson, M.D., of Mount Sinai School of Medicine. "But because the amount patients could consume without serious reaction would be greatly increased, the fear of accidental ingestion that detracts from quality of life for many patients would be eliminated.”





Related Links:
Tanox
National Jewish Medical and Research Center
Mount Sinai School of Medicine

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Patient Preoperative Skin Preparation
BD ChloraPrep
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Half-matched bone marrow transplant expands access to curative treatment for children and young adults with severe aplastic anemia. (Photo courtes of Margarita Dionysiou using Bio Render)

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Severe aplastic anemia is a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells, leaving children and young adults vulnerable to anemia, infection, and bleeding.... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.